In the Guidance for Industry from the Food and Drug Administration in 2008. excess cardiovascular risk should be ruled out in trials of all new antidiabetic drugs; however. relatively few studies have focused on cardiovascular safety with antidiabetic drug use. We aimed to examine mortality and cardiovascular risk using a network meta-analysis. https://mabelandfoxs.shop/product-category/toothbrush/